Short-course therapy with zidovudine plus lamivudine for prevention of mother-to-child transmission of human immunodeficiency virus type 1 in Thailand

Clinical Infectious Diseases

Volumn 35, Issue 11, 2002, Pages 1405-1413

  Chaisilwattana, Pongsakdi ^a   Chokephaibulkit, Kulkanya ^a   Chalermchockcharoenkit, Amphan ^a   Vanprapar, Nirun ^a   Sirimai, Korakot ^a   Chearskul, Sanay ^a   Sutthent, Ruengpung ^a   Opartkiattikul, Nisarat ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; LAMIVUDINE; ZIDOVUDINE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BOTTLE FEEDING; CONFIDENCE INTERVAL; CONGENITAL MALFORMATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LABOR; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; SHORT COURSE THERAPY; SIDE EFFECT; T LYMPHOCYTE; THAILAND; THIRD TRIMESTER PREGNANCY; THROMBOCYTOPENIA; VIRUS LOAD; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; DISEASE TRANSMISSION, VERTICAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; PROSPECTIVE STUDIES; THAILAND; ZIDOVUDINE;

EID: 0036904870     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/344274     Document Type: Article

References (19)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331:1173-80.
2. Culnane M, Fowler M, Lee SS, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA 1999; 281:151-7.
3. Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: A randomised trial. Lancet 1999; 353(9155):781-5.
4. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998; 339:1409-14.
5. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal H1V-1 transmission in Bangkok, Thailand: A randomised controlled trial. Lancet 1999; 353(9155):773-80.
6. Mandelbrot L, Mascaaro AL, Rekacewicz C, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001; 285:2083-93.
7. Silverman NS, Watts DH, Hitti J, et al. Initial multicenter experience with double nucleoside therapy for human immunodeficiency virus infection during pregnancy. Infect Dis Obstet Gynecol 1998; 6:237-43.
8. Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. JAMA 1996; 276:118-25.
9. US National Institute of Allergy and Infectious Disease, Division of AIDS Regulatory Operations Center. Serious Adverse Experiences Reporting Manual. Rockville, MD: National Institute of Allergy and Infectious Diseases, 1998.
10. Amornwichet P, Teeraratkul A, Simonds RJ, et al. Preventing mother-to-child transmission: The first year of Thailand's national program. JAMA 2002; 288:245-8.
11. Kanshana S, Simonds RJ. National program for preventing mother-child HIV transmission in Thailand: Successful implementation and lessons learned. AIDS 2002; 16:953-9.
12. Mofensson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N Engl J Med 1999; 341:385-93.
13. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med 1999; 341:394-402.
14. De Cock KM, Fowler MG, Mercieer E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: Translating research into policy and practice. JAMA 2000; 283:1175-82.
15. Kuhn L, Steketee RW, Weedon J, et al. Distinct risk factors for intrauterine and intrapartum human immunodeficiency virus transmission and consequences for disease progression in infected children. J Infect Dis 1999; 179:52-8.
16. Kalish LA, Pitt J, Lew J, et al. Defining the time of fetal or perinatal acquisition of human immunodeficiency virus type 1 infection on the basis of age at first positive culture. J Infect Dis 1997; 175:712-5.
17. Saba J, on behalf of the PETRA Trial Study Team. Interim analysis of early efficacy of three short ZDV/3TC combination regimens to prevent mother-to-child transmission of HIV-1: The PETRA trial [abstract S-7]. In: Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1999. Available at: http://www.retroconference.org.
18. Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for the Use of Antiretroviral Drugs in Pregnant HIV-infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States. 24 January 2001. Available at: http://www.hivatis.org. Accessed on 25 February 2001.
19. Mandelbrot L, Peytavin G, Firtion G, Farinotti R. Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women. Am J Obstet Gynecol 2001; 184:153-8.